Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study

Arch Intern Med. 2012 Aug 13;172(15):1182-4. doi: 10.1001/archinternmed.2012.2271.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Double-Blind Method
  • Drug Monitoring / methods
  • Female
  • Fingers* / blood supply
  • Fingers* / physiopathology
  • Half-Life
  • Humans
  • Imidazoles* / administration & dosage
  • Imidazoles* / adverse effects
  • Imidazoles* / pharmacokinetics
  • Laser-Doppler Flowmetry / methods
  • Male
  • Phosphodiesterase 5 Inhibitors / administration & dosage
  • Phosphodiesterase 5 Inhibitors / adverse effects
  • Phosphodiesterase 5 Inhibitors / pharmacokinetics
  • Piperazines* / administration & dosage
  • Piperazines* / adverse effects
  • Piperazines* / pharmacokinetics
  • Raynaud Disease* / diagnosis
  • Raynaud Disease* / drug therapy
  • Raynaud Disease* / physiopathology
  • Regional Blood Flow / drug effects*
  • Sulfones / administration & dosage
  • Sulfones / adverse effects
  • Sulfones / pharmacokinetics
  • Treatment Outcome
  • Triazines / administration & dosage
  • Triazines / adverse effects
  • Triazines / pharmacokinetics
  • Vardenafil Dihydrochloride

Substances

  • Imidazoles
  • Phosphodiesterase 5 Inhibitors
  • Piperazines
  • Sulfones
  • Triazines
  • Vardenafil Dihydrochloride